Pfizer (PFE)
Pfizer Book Value per Share: 11.10
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
PFE Book Value per Share Rankings
| Overall | 58th percentile | 1840 of 4382 |
| Sector | 77th percentile | 116 of 505 in Healthcare |
| Industry | 68th percentile | 8 of 25 in Drug Manufacturers - Major |
PFE Book Value per Share Range, Past 5 Years
| Minimum | 8.552 | Dec 2008 |
| Maximum | 11.60 | Sep 2011 |
| Average | 10.32 |
About Book Value per Share
Book value per share indicates the book value (or accounting value) of each share of stock. Book value is a company's net asset value, which is calculated by total assets minus intangible assets and liabilities. A relatively high book value per share in relation to stock price often occurs when a stock is undervalued.
In the rare circumstance that market price falls below the book value per share, generally a stock is undervalued and might be an attractive buy.
Learn More
You may also be interested in these PFE related companies
PFE News
$AMRN I would be surprised if $PFE isn't having backchannel talks pre-889.$AMRN is a perfect takeout...very few employees and cinch approval
about 7 hours ago by InTheBarn
about 7 hours ago by InTheBarn
Drug Stocks In The Spotlight At ASCO Conference. $JNJ $CELG $ONXX $RHHBY $PFE http://stks.co/42e8
about 17 hours ago by abubnic
about 17 hours ago by abubnic
@SciGuy $DRRX I don't believe so; the fortunes of DURECT are tied to $PFE and Remoxy
about 20 hours ago by SlownSteady
about 20 hours ago by SlownSteady
@SCarolinaguy $DRRX licensed the drug to $PTIE; $PTIE licensed it to King and $PFE bought King; I think people might forget about $DRRX
about 21 hours ago by SlownSteady
about 21 hours ago by SlownSteady
@SlownSteady Sounds encouraging with $PFE supporting. What is the relationship? Surely their support would lead to approval
about 21 hours ago by SCarolinaguy
about 21 hours ago by SCarolinaguy
@SCarolinaguy $DRRX $PFE plans to resubmit the NDA. The company has other products; a recent filed trial triggered share price punishment
about 21 hours ago by SlownSteady
about 21 hours ago by SlownSteady
@SCarolinaguy $DRRX Only insiders know. CMC problems are usually resolved. $PFE will have new data and meet with the FDA
about 21 hours ago by SlownSteady
about 21 hours ago by SlownSteady
RT @Glopolon: Does it matter, they are next door to $PFE $AMRN /i live next to a lawyer. odds of being sued increased day they moved in. Hmm
about 4 days ago by ITradeforMe
about 4 days ago by ITradeforMe
RT @Glopolon $AMRN $PFE 'I wanna get close to you' Rose Royce http://stks.co/404L <Hmmmmmmmm!?$$$
about 4 days ago by Bleedblue
about 4 days ago by Bleedblue
$AMRN $PFE 'I wanna get close to you' Rose Royce http://stks.co/404H
about 4 days ago by Glopolon
about 4 days ago by Glopolon
@SomeGuy900 @christy155 $DRXX If $PFE gets a class 2 resubmission, they'll know in Q2/Q3 of next year; class one they'll know in Q1/Q2 '13
about 5 days ago by SlownSteady
about 5 days ago by SlownSteady
@SomeGuy900 @christy155 $DRXX The $PFE discussions with the FDA should be in Q3; I imagine they will resubmit in early 2013
about 5 days ago by SlownSteady
about 5 days ago by SlownSteady
@SomeGuy900 @christy155 The last comment from $DRRX management was that $PFE was getting ready to talk to the FDA about some more studies
about 5 days ago by SlownSteady
about 5 days ago by SlownSteady
@SomeGuy900 @christy155 $DRRX I have no idea what's going on. It's gone up 20 cents since I bought in. Maybe $PFE will talk with the FDA
about 5 days ago by SlownSteady
about 5 days ago by SlownSteady
Pfizer (PFE) Promotes Olivier Brandicourt to GM of Emerging Markets, Established Products Units
May 23, 7:31AM Street Insider
May 23, 7:31AM Street Insider
Pfizer (PF) Updates on Effect of Lyrica on Pain in Fibromyalgia Patients
May 18, 8:02AM Street Insider
May 18, 8:02AM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| PFE | 21.87 | -0.17 | -0.77% | 166.12B |
| PETM | 64.47 | +0.02 | +0.03% | 7.082B |
| PETD | 24.80 | +0.06 | +0.22% | 584.84M |
| PERY | 18.82 | -0.07 | -0.37% | 296.95M |
| PERI | 3.86 | -0.19 | -4.69% | 40.18M |
| PERF | 7.80 | -0.01 | -0.13% | 70.06M |
| PER | 19.93 | -0.07 | -0.35% | 787.60M |
| PEP | 67.99 | -0.23 | -0.34% | 108.30B |
| PEOP | 16.08 | +0.33 | +2.10% | |
| PEO | 23.01 | -0.18 | -0.78% |